Skip to contentM
Marimed Inc.
M
MRMDMarimed Inc. Q3 2024 · 10-Q
Revenue$40.60M$40.60M+4.6% vs Q3 2023 Net Income-$1.01M-$1.01MN/M vs Q3 2023 EPS Diluted$0.00$0.00N/M vs Q3 2023 Gross Profit$16,782,000−0.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marimed Inc. · CIK 1522767 · Engraved from SEC EDGAR
Operating Cash Flowderived$803,000−89.8% Free Cash Flowderived-$1,763,000N/M Margins · derivedGross margin41.3%−2.1 pt vs Q3 2023
Operating margin3.3%−5.2 pt vs Q3 2023
Net margin-2.5%+8.5 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 7, 2024 · 38 d after period end